Table 8 Availability of medicines for hypertension and diabetes, by health facility level
Pharmaceutical Classes | RRH (N = 13) | GH (N = 26) | HCIV (N = 14) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
No. that have drug available | Stockout in last quarter | Stockout in last year | No. that have drug available | Stockout in last quarter | Stockout in last year | No. that have drug available | Stockout in last quarter | Stockout in last year | ||
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||
Hypertension | ||||||||||
 Thiazide diuretic | 12 (92.3) | 1 (7.7) | 2 (15.4) | 23 (88.5) | 3 (11.5) | 2 (7.7) | 9 (64.3) | 3 (21.4) | 2 (14.3) | |
 Calcium channel blocker | 12 (92.3) | 1 (7.7) | 1 (7.7) | 22 (84.6) | 2 (7.7) | 3 (11.5) | 14 (100.0) | 4 (28.6) | 5 (35.7) | |
 Beta-blocker | 7 (53.8) | 3 (23.1) | 3 (23.1) | 14 (53.8) | 9 (34.6) | 7 (26.9) | 13 (92.9) | 3 (21.4) | 3 (21.4) | |
 ACE inhibitor | 10 (76.9) | 2 (15.4) | 2 (15.4) | 20 (76.9) | 5 (19.2) | 6 (23.1) | 6 (42.9) | 2 (14.3) | 2 (14.3) | |
 Others (e.g. Methyldopa, hydralazine, magnesium sulphate) | 10 (76.9) | 2 (15.4) | 2 (15.4) | 20 (76.9) | 2 (7.7) | 5 (19.2) | 9 (64.3) | 3 (21.4) | 2 (14.3) | |
Diabetes | ||||||||||
 Biguanides | 12 (92.3) | 0 (0.0) | 0 (0.0) | 23 (88.5) | 4 (15.4) | 2 (7.7) | 14 (100.0) | 4 (28.6) | 5 (35.7) | |
 Sulfonylureas | 11 (84.6) | 2 (15.4) | 2 (15.4) | 21 (80.8) | 6 (23.1) | 2 (7.7) | 11 (78.6) | 3 (21.4) | 4 (28.6) | |
 Thiazolidinediones | 1 (7.7) | 2 (15.4) | 2 (15.4) | 2 (7.7) | 5 (19.2) | 4 (15.4) | 1 (7.1) | 1 (7.1) | 1 (7.1) | |
 Dipeptidyl peptidase-4 inhibitors |  | 1 (7.7) | 1 (7.7) | 1 (3.8) | 5 (19.2) | 4 (15.4) | 1 (7.1) | 1 (7.1) | 0 (0.0) | |
 Alpha-glucosidase inhibitors |  | 1 (7.7) | 1 (7.7) | 2 (7.7) | 5 (19.2) | 5 (19.2) | 0 (0.0) | 0 (0.0) | 1 (7.1) | |
Insulin type | Ultra short-acting | 8 (61.5) | 1 (7.7) | 0 (0.0) | 9 (34.6) | 3 (11.5) | 6 (23.1) | 3 (21.4) | 0 (0.0) | 0 (0.0) |
Short-acting | 9 (69.2) | 3 (23.1) | 3 (23.1) | 14 (53.8) | 2 (7.7) | 6 (23.1) | 5 (35.7) | 1 (7.1) | 1 (7.1) | |
Intermediate | 10 (76.9) | 3 (23.1) | 5 (38.5) | 12 (46.2) | 4 (15.4) | 6 (23.1) | 3 (21.4) | 0 (0.0) | 0 (0.0) | |
Long-acting | 11 (84.6) | 3 (23.1) | 4 (30.8) | 14 (53.8) | 3 (11.5) | 5 (19.2) | 3 (21.4) | 1 (7.1) | 1 (7.1) | |